Since the publication of this Review Article, we noticed several mistakes in Table 2 and the Perspective section that need to be corrected immediately.
In Table 2 , the status of AAB-003 Phase I trial is completed. In addition, the status of GV-971 Phase III trial is completed in China. The correct portion of Table 2 is displayed as below.
In the perspective section, the sigma-1 receptor activator Anavex 2-73 has entered a phase III clinical trial but it was not granted fast-track status by the FDA. Therefore, the texts should be corrected to "In addition, fluoxetine can bind to the endoplasmic reticulum protein sigma-1 receptor. 418 Sigma-1 receptor ligands can enhance acetylcholine secretion. 419, 420 The sigma-1 receptor is located in the mitochondrion-associated ER membrane so that the activation of the sigma-1 receptor can prolong Ca 2+ signaling in mitochondria. 421 Consequently, the local and specific elevation of [Ca 2+ ] in the mitochondrial matrix can enhance ATP synthesis, 422,423 which ameliorates hypometabolism. Interestingly, Anavex 2-73, a sigma-1 receptor activator is now in phase III clinical trial."
The key messages of the article are not affected by these corrections. We apologize for these inadvertent mistakes.
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